MedDataX Logo

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

NCT01922037 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 806

Last updated 2017-12-11

Study results available
· View outcomes & findings →

Summary

This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.

Conditions

  • Asthma

Interventions

DRUG

Omalizumab

Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.

Sponsors & Collaborators

  • Hoffmann-La Roche

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-19
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01922037 on ClinicalTrials.gov